BIOMAT Database Logo BIOMAT Database Logo

Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary. 2014

Kayo Suzuki, and Satoshi Takakura, and Motoaki Saito, and Asuka Morikawa, and Jiro Suzuki, and Kazuaki Takahashi, and Chie Nagata, and Nozomu Yanaihara, and Hiroshi Tanabe, and Aikou Okamoto
*Department of Obstetrics and Gynecology, The Jikei University Kashiwa Hospital, Kashiwa; and †Department of Obstetrics and Gynecology, The Jikei University School of Medicine; ‡Department of Obstetrics and Gynecology, The Jikei University Daisan Hospital; and §Department of Obstetrics and Gynecology, The Jikei University Katsushika Medical Center, Tokyo, Japan.

OBJECTIVE The aim of this study was to evaluate the impact of surgical staging in stage I clear cell adenocarcinoma of the ovary (CCC). METHODS We performed a retrospective review of 165 patients with stage I CCC treated with optimal or nonoptimal staging surgery. RESULTS The median follow-up period in this study was 67 months. No significant difference was detected in recurrence-free survival (RFS) or overall survival (OS) between patients optimally and nonoptimally staged (RFS: P = 0.434; OS: P = 0.759). The estimated 5-year RFS and OS rates were 92.1% and 95.3% in patients with stages IA/IC1 and 81.0% and 83.7% in stages IC2/IC3, respectively. The multivariate analysis indicated that stages IC2/IC3 predicted worse RFS and OS than stages IA/IC1 in stage I CCC patients (RFS: P = 0.011; OS: P = 0.011). Subsequently, we investigated the impact of surgical staging, respectively, in stages IA/IC1 and stages IC2/IC3. Significant differences were observed in PFS and OS between patients optimally and nonoptimally staged with stages IA/IC1 (RFS: P = 0.021; OS: P = 0.024), but no significant difference was found in those with stages IC2/IC3. The multivariate analysis indicated that nonoptimal staging surgery predicted worse RFS than the optimal staging surgery in stages IA/IC1 CCC patients (P = 0.033). In addition, we investigated the impact of surgical staging for stages IA/IC1 in the adjuvant chemotherapy group. The 5-year RFS and OS rates in patients optimally and nonoptimally staged with stages IA/IC1 in the adjuvant chemotherapy group were 97.8% and 100%, and 85.2% and 89.4%, respectively. The multivariate analysis indicated that nonoptimal staging surgery predicted worse RFS than the optimal staging surgery for stages IA/IC1 patients in the adjuvant chemotherapy group (P = 0.019). CONCLUSIONS The prognosis for women with stage 1A/IC1 is very good. Surgical staging category was the only independent prognostic factor for RFS in stages IA/IC1 CCC.

UI MeSH Term Description Entries
D008197 Lymph Node Excision Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966) Lymph Node Dissection,Lymphadenectomy,Dissection, Lymph Node,Dissections, Lymph Node,Excision, Lymph Node,Excisions, Lymph Node,Lymph Node Dissections,Lymph Node Excisions,Lymphadenectomies,Node Dissection, Lymph,Node Dissections, Lymph
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003949 Diagnostic Techniques, Surgical Methods and procedures for the diagnosis of disease or dysfunction by examination of the pathological site or operative field during surgical intervention. Diagnostic Technic, Surgical,Diagnostic Technics, Surgical,Diagnostic Technique, Surgical,Surgical Diagnostic Technic,Surgical Diagnostic Technics,Surgical Diagnostic Technique,Surgical Diagnostic Techniques,Technic, Surgical Diagnostic,Technics, Surgical Diagnostic,Technique, Surgical Diagnostic,Techniques, Surgical Diagnostic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Kayo Suzuki, and Satoshi Takakura, and Motoaki Saito, and Asuka Morikawa, and Jiro Suzuki, and Kazuaki Takahashi, and Chie Nagata, and Nozomu Yanaihara, and Hiroshi Tanabe, and Aikou Okamoto
Local therapy in stage I clear cell adenocarcinoma of the vagina.
September 1987, Cancer,
Kayo Suzuki, and Satoshi Takakura, and Motoaki Saito, and Asuka Morikawa, and Jiro Suzuki, and Kazuaki Takahashi, and Chie Nagata, and Nozomu Yanaihara, and Hiroshi Tanabe, and Aikou Okamoto
Papillary clear cell adenocarcinoma of the ovary.
September 1949, American journal of obstetrics and gynecology,
Kayo Suzuki, and Satoshi Takakura, and Motoaki Saito, and Asuka Morikawa, and Jiro Suzuki, and Kazuaki Takahashi, and Chie Nagata, and Nozomu Yanaihara, and Hiroshi Tanabe, and Aikou Okamoto
Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
December 2010, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Kayo Suzuki, and Satoshi Takakura, and Motoaki Saito, and Asuka Morikawa, and Jiro Suzuki, and Kazuaki Takahashi, and Chie Nagata, and Nozomu Yanaihara, and Hiroshi Tanabe, and Aikou Okamoto
PTEN expression in clear cell adenocarcinoma of the ovary.
April 2006, Gynecologic oncology,
Kayo Suzuki, and Satoshi Takakura, and Motoaki Saito, and Asuka Morikawa, and Jiro Suzuki, and Kazuaki Takahashi, and Chie Nagata, and Nozomu Yanaihara, and Hiroshi Tanabe, and Aikou Okamoto
Recurrent stage I endometrial adenocarcinoma in the nonirradiated patient: preliminary results of surgical "staging".
February 1993, Gynecologic oncology,
Kayo Suzuki, and Satoshi Takakura, and Motoaki Saito, and Asuka Morikawa, and Jiro Suzuki, and Kazuaki Takahashi, and Chie Nagata, and Nozomu Yanaihara, and Hiroshi Tanabe, and Aikou Okamoto
Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary.
January 2016, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Kayo Suzuki, and Satoshi Takakura, and Motoaki Saito, and Asuka Morikawa, and Jiro Suzuki, and Kazuaki Takahashi, and Chie Nagata, and Nozomu Yanaihara, and Hiroshi Tanabe, and Aikou Okamoto
Glypican-3 expression in clear cell adenocarcinoma of the ovary.
June 2009, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Kayo Suzuki, and Satoshi Takakura, and Motoaki Saito, and Asuka Morikawa, and Jiro Suzuki, and Kazuaki Takahashi, and Chie Nagata, and Nozomu Yanaihara, and Hiroshi Tanabe, and Aikou Okamoto
Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types.
December 2011, Gynecologic oncology,
Kayo Suzuki, and Satoshi Takakura, and Motoaki Saito, and Asuka Morikawa, and Jiro Suzuki, and Kazuaki Takahashi, and Chie Nagata, and Nozomu Yanaihara, and Hiroshi Tanabe, and Aikou Okamoto
The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study.
November 2009, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Kayo Suzuki, and Satoshi Takakura, and Motoaki Saito, and Asuka Morikawa, and Jiro Suzuki, and Kazuaki Takahashi, and Chie Nagata, and Nozomu Yanaihara, and Hiroshi Tanabe, and Aikou Okamoto
Survival impact of adjuvant paclitaxel and carboplatin for early-stage ovarian clear-cell carcinoma with complete surgical staging.
January 2011, Gynecologic and obstetric investigation,
Copied contents to your clipboard!